DISCLAIMER: GOLDINVESTMENTCOMPANIES.COM IS AN AFFILIATED PARTNER FOR GOLDCO PRECIOUS METALS, AUGUSTA PRECIOUS METALS, AND BIRCH GOLD GROUP, PROMOTING THEIR GOLD IRA, GOLD 401K TRANSFER AND BITCOIN IRA SERVICES AND PRODUCTS.
Sirona Biochem (TSXV:SBM) reveals positive results of a clinical study on their active ingredient TFC-1067. Sirona Biochem CEO Dr. Howard Verrico says they’re charged up to succeed in both the #cosmetic and #therapeutic spaces.
“We apply our technology to improve the efficiency of molecules, fuse their efficacy, from reduced toxicity, and just make a better compound. So there are opportunities to come up in multiple fields leading us into the cosmetic space and also into the therapeutic space. The cosmetic space is a much shorter path to commercialization, while the therapeutics is a more traditional, but very rewarding path. So we take advantage of both opportunities,” said Dr. Verrico.
TFC-1067 is a synthetic active and a part of the arbutin family. Sirona’s proprietary platform technology advances this ingredient to correct dark spots and other medical conditions such as hyperpigmentation, melasma, vitiligo, and rosacea.
“We’ve come up with a molecule which we believe is an industry leader because it is both safe and effective. It’s an enormous breakthrough so we’re bringing an opportunity for people to have dark spots or uneven skin tone to safely treat those and do so effectively.”
In March 2021, Sirona Biochem launched its first commercial product containing TFC-1067, which debuted as the active ingredient in New Rodan + Fields REVERSE Targeted Dark Spot Corrector.
“We conducted further analysis with one of the top large pharmaceutical companies in the world. And we had a very successful clinical trial and we’re entering a phase to process a licensing deal. Our goal is to develop a global licensing with this partner and bring this compound to global success.”
Investing News Network (INN)
Find out more about investing by INN @
Want a FREE investor kit? Download here↓
Follow us Facebook:
Follow us on Twitter:
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.